92 results about "Dyskinesia" patented technology

The invention discloses a Parkinson's dyskinesia individualized SCAN network positioning method based on a multi-modal image and deep learning. The method comprises the steps of obtaining multi-modal medical image data, preprocessing the multi-modal medical image data, obtaining a multi-modal structure image and functional connection data, and calculating a spontaneous neural activity index of a whole-brain voxel level; taking a priori brain region related to the spontaneous neural activity index and dyskinesia as a seed point, constructing a seed point voxel function connection graph representing individual brain function connection, and performing nonlinear feature fusion and extraction through the deep learning network model; the bilinear attention network is adopted to capture the interaction information of the feature data and the individual dyskinesia symptom which is significantly related, an individualized SCAN network positioning result is obtained, the structure-function coupling characteristics of the individual brain are comprehensively described, the cross-modal pathological features related to the dyskinesia can be more sensitively recognized, and the accuracy and accuracy of the diagnosis and treatment of the dyskinesia can be improved. And the accuracy and robustness of abnormal brain region detection are obviously improved.

The invention relates to the technical field of data processing, and discloses a gait rehabilitation evaluation method and system based on spatial-temporal characteristics of multi-modal data, a terminal and a storage medium, and the method comprises the steps: synchronously collecting myoelectricity, electroencephalogram and exoskeleton robot IMU signals of a dyskinesia crowd in a certain motion normal form in a specific period interval; a motion function scoring result of a doctor on a patient according to a scale is synchronously recorded, data preprocessing, channel selection and feature extraction are performed on myoelectricity, electroencephalogram and exoskeleton robot IMU signals, a model is established based on a neural network, motion evaluation is performed according to a fused feature array, and a motion function quantitative score is obtained; and the motion function state of the evaluated person is graded according to the score. According to the method, the multi-modal synchronous data rehabilitation evaluation model of the movement function of the dyskinesia crowd is constructed according to multiple information mining, and the movement function state of the evaluated person is rapidly evaluated, predicted and graded.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The invention discloses a daily life activity ability assessment method and system based on a multi-branch space-time fusion network. The method comprises the steps of collecting motion data of a to-be-evaluated object, performing segmentation, noise reduction and standardization preprocessing, and extracting time-frequency domain features and motion deviation degree, motion similarity index and bilateral symmetry index provided by the invention; obtaining a uniform Bhattacharyya index scale score; and taking the motion feature data set and the clinical score as input, performing training based on a multi-branch space-time fusion algorithm, constructing a multi-task prediction model, and realizing automatic evaluation of the ADL. According to the method, the multi-branch space-time fusion network is innovatively introduced, the relevance between tasks is fully utilized, the spatial feature extraction capability is enhanced in combination with the graph neural network, adaptive fusion of the features is realized through a cross-layer interactive attention mechanism, the model prediction precision and evaluation reliability are remarkably improved, and the method is suitable for large-scale popularization and application. And an effective technical support is provided for rehabilitation evaluation and personalized treatment of patients with dyskinesia and disability and dementia.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating Parkinson's disease, namely tremor syndrome of traditional Chinese medicine, which comprises the following raw materials by weight: 390-470g of liver calming and wind calming medicine, 140-160g of radix rehmanniae, 280-320g of radix paeoniae alba, 840-960g of first decoction medicine, 390-450g of blood activating and qi regulating and tendon and collateral dredging medicine, and 305-355g of antidote. The traditional Chinese medicine composition has remarkable effects of relaxing tendons and detoxifying, and calming endogenous wind and arresting fibrillation, can play a role in solving the problems of head shaking, limb tremor, muscle stiffness, dyskinesia and the like caused by liver wind internal movement and kidney deficiency and toxic damage of Parkinson's disease, and can nourish liver and kidney, relieve tendon and vessel contracture and relieve pain due to the synergistic effect of various traditional Chinese medicinal materials contained in the traditional Chinese medicine composition. The traditional Chinese medicine composition is especially suitable for Parkinson patients with liver-wind internal movement and kidney deficiency and toxicity loss, and can gradually improve the neurotransmitter level in the brain after being taken. The traditional Chinese medicine composition has an outstanding detoxification effect, can effectively remove accumulation of pathological products such as phlegm and blood stasis in the body of the Parkinson's disease patient, prevents phlegm and blood stasis from generating toxins, and can relieve medicine poison generated by long-term medicine taking of the patient.

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.

The invention discloses a flexible shoulder rehabilitation exoskeleton based on a pneumatic folding driver, and the flexible shoulder rehabilitation exoskeleton comprises a trunk module, a shoulder module, a connecting assembly, a flexible folding pneumatic driving module, a multi-mode sensing module and a control terminal. By introducing the design of alternating internal folding and external folding, geometric dislocation between the driver and the joint axis is effectively compensated, and continuous high output torque is provided. The control system recognizes the motion intention of a user by collecting surface electromyogram signals and inertia measurement data through threshold judgment logic, and adjusts an electromagnetic proportional valve through a PID algorithm in combination with feedback of an air pressure sensor to achieve closed-loop accurate control over air pressure. The device has the advantages of light weight, high wearing comfort and excellent mechanical transparency, muscle load in rehabilitation training can be remarkably reduced, and the device is suitable for daily assistance and rehabilitation training of patients suffering from upper limb dyskinesia.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present disclosure relates to compositions and methods for the treatment of dyskinesia using a pharmaceutical composition comprising 3-methylmethcathinone (3MMC), or a pharmaceutically acceptable salt thereof.

The invention discloses a pharmaceutical composition for preventing and / or treating Parkinson's disease and application of the pharmaceutical composition, and relates to the technical field of biological medicine. The composition comprises nervonic acid, salvianolic acid A and pharmaceutically acceptable auxiliary materials. Experiments prove that the composition can improve intestinal flora, obviously promote alleviation of symptoms of a Parkinson's disease model animal, promote regeneration of dopaminergic neuronal cells and neural stem cells, relieve neuroinflammation, promote repair of damaged nerves, improve dyskinesia of mice caused by Parkinson's disease and improve the Parkinson's disease resistance of the mice. Therefore, the polypeptide has potential application value in treatment of the human Parkinson's disease. According to the invention, the effect of the composition is confirmed from the perspective of improving the change of intestinal flora by utilizing the relationship of the brain-intestinal axis, and a basis is provided for intervening the treatment of Parkinson's disease through the intestinal flora.

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

The invention discloses a multi-degree-of-freedom bionic foot rehabilitation robot device which comprises an outer frame, a four-section bionic foot bottom plate and a parallel driving mechanism. The four-section type bionic foot bottom plate is connected through a rotating shaft hinge and a sliding block and sliding rod structure, and biomechanical movement of a foot posterior area, a foot middle area, a foot anterior area and a phalanx area of a human foot is simulated. And the parallel driving mechanism realizes multi-degree-of-freedom movement and deformation compensation of the ankle joint and the foot by adjusting the posture of each foot bottom plate section. The device can be worn on the foot and is suitable for rehabilitation training of patients with lower limb dyskinesia.

The application discloses a kind of Thy1-SNCA;Clu gene knockout mouse model construction method and application, the model construction method is: Thy1-SNCA mouse is crossed with Clu-KO mouse and F1 generation is obtained, and Thy1-SNCA;Clu- / + mouse is obtained by identification;Thy1-SNCA;Clu- / + mouse is crossed back with Clu-KO mouse and F2 generation is obtained, and the mouse of target genotype, i.e. Thy1-SNCA;Clu- / - mouse is obtained by identification.The Thy1-SNCA;Clu- / - mouse constructed by the application can effectively shorten the time point of the appearance of parkinsonian movement disorder, thereby shortening the experimental period, and providing more model mouse selection for PD research.

The invention discloses a soft clothing device for shoulder joint full-degree-of-freedom auxiliary movement based on SMA driving, relates to the technical field of shoulder rehabilitation treatment, and solves the problems that a shoulder rehabilitation exoskeleton robot is heavy in overall system, large in size, poor in portability and likely to cause secondary injury to a patient in the use process. The chest side and the back side of a wearer are each provided with an inner-layer waistcoat in a wearing mode, and the six SMA driving units of each driving device are used for driving the six fixing ring buckles so as to drive shoulder joints on the left side or the right side of the human body to move. According to the invention, the extension and contraction of the SMA spring are controlled, so that the shoulder joint of a patient can be effectively driven to move in three degrees of freedom through the extension and contraction of the PE wire, and the patient with shoulder injury can be effectively driven to complete the three-degree-of-freedom movement of contraction and expansion, flexion and extension and internal and external rotation, so that the disease of the patient with shoulder dyskinesia can be effectively relieved.

The invention discloses a Parkinson's disease dyskinesia recognition system based on cross-frequency coupling tensor decomposition, and the system comprises a signal collection and processing module which is used for synchronously collecting and preprocessing local field potential signals of multiple sites of a brain; the cross-frequency coupling calculation module is used for calculating a cross-frequency coupling map of each data slot; the signal-to-noise ratio balance processing module is used for generating an average cross-frequency coupling map of each tested individual; the tensor decomposition feature extraction module is used for aggregating the average cross-frequency coupling maps of all the tested individuals, constructing a third-order tensor and decomposing the third-order tensor to obtain three tensor components; moreover, when the average cross-frequency coupling atlas of the tested individual to be tested is input, weight vectors corresponding to the three tensor components are output; and the classification and identification module is used for inputting the weight vector of the tested individual to be tested into a pre-trained machine learning classification model and outputting an identification result of the dyskinesia of the Parkinson's disease. According to the method, the problem of frequency drift existing among different individuals can be solved, and the recognition accuracy is improved.

The application provides application of N-acyl dopamine family lipids in prevention and treatment of drug-induced Parkinson's disease motor complications, and belongs to the field of biological medicine. The application first proposes that the NADs compound can be used as a levodopa companion drug for preventing or treating levodopa-induced dyskinesia. The application takes 6-hydroxydopamine intracerebral injection and intraperitoneal injection of levodopa of an LID animal model as a research object, and studies the effect of NADs on improving LID. The results show that the NADs of the application can significantly improve the drug-induced PD motor complications LID, and it is proved that the NADs compound can be used as a companion drug to assist levodopa in treating PD.

The application discloses a gait intervention method for a dyskinesia disease population, a music generation method, device, system, equipment and medium, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: in the process that a target object suffering from a dyskinesia disease is intervened and treated according to abnormal gait by rhythm music, collecting multi-modal physiological data of the target object in real time, and dynamically determining a plurality of motion symptom characteristic indexes related to gait of the target object according to the multi-modal physiological data; determining music parameters at each moment in real time according to the plurality of motion symptom characteristic indexes; dynamically adjusting notes of the rhythm music at each moment according to the music parameters at each moment, and generating rhythm music adapted to the current gait condition of the target object. According to the scheme, the rhythm music can be more comprehensively and individually dynamically adjusted, and is more suitable for the current gait condition of the target object, so that the effect of abnormal gait rehabilitation treatment, intervention and correction can be improved.

Pharmaceutical composition for use in the prophylactic and / or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA.

Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

Apparatus and methods for utilizing a soft robot to facilitate standing and / or walking of pediatric patients, particularly patients suffering from dyskinesia, such as cerebral palsy. Such a soft robotic device may include a fabric pneumatic actuator that, upon inflation, generates the necessary torque along upper and lower contacts of the device to assist in movement of the patient, particularly in joint extension walking, standing, or sitting-to-standing movement. Compared with a fabric pneumatic actuator with an upright or isotropic structure, the concave structure can provide a larger torque angle and can also avoid friction and extrusion generated at the glenoid fossa. The actuator is soft, light in mass, good in compliance, and capable of providing comfortable joint extension in a multi-center trajectory. The actuator can be incorporated into a joint protector or an exoskeleton, and is very suitable for sensitive, soft and weak pediatric patients with dyskinesia, especially infants with cerebral palsy.

The invention relates to the technical field of medicines, in particular to application of songorine in treatment of Parkinson's disease. The C20-type diterpenoid alkaloid songnin provided by the invention can obviously and continuously improve dyskinesia caused by dopaminergic neuron injury in MPTP-induced Parkinson's disease model mice, and the onset dose of songnin is obviously lower than that of clinically common positive medicine, namely medoxolane, so that the songnin shows a stronger drug effect and can be used for preparing drugs for treating Parkinson's disease. The compound can be developed into a novel efficient anti-Parkinson disease treatment medicine.

The invention relates to the technical field of dyskinesia, in particular to application and a system of a gene marker combination in preparation of a Parkinson's disease dyskinesia risk assessment product, and the gene marker combination comprises COMT rs4680, MAOB rs1799836, GBA, DRD2 rs2283265, DRD3 rs6280, LRRK2 G2385R, BDNF rs6265, HOMER1 rs4704559 and SLC6A3 rs28363170. Wherein the product is used for calculating the dyskinesia risk value by detecting the genotype of the gene marker. According to the method, nine genetic markers and multi-modal clinical data are integrated, the risk probability is dynamically calculated based on the Bayesian algorithm, an individual intervention scheme is output, and early-stage accurate prevention and control are achieved.

The invention relates to an isotope labeled trapidil derivative. In particular, isotope labeled trapidil derivatives useful in the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are provided. The isotope labeled trapidil derivative comprises a deuterated trapidil derivative. In addition, combination therapies of isotopically labeled trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and dyskinesia associated with Parkinson's disease are also provided.

The invention discloses an intent recognition system and method for disabled old people based on gaze and environment interaction, and belongs to the technical field of intelligent old people care and artificial intelligence. The invention aims to solve the problem of difficult communication of disabled old people caused by language and dyskinesia. The system comprises a multi-modal data acquisition unit which is used for acquiring staring target sequences and multi-dimensional situation information such as physiology, time, space and the like of old people; the situation feature fusion and construction unit is used for integrating the multi-source heterogeneous data into structured comprehensive situation representation; the core of the intention reasoning unit is a large language model, and the intention reasoning unit is used for carrying out deep semantic understanding and logical reasoning on the comprehensive situation and generating a candidate intention list with confidence; and the man-machine interaction output unit is used for presenting the recognition result to nursing personnel. According to the method, the staring behaviors and the rich situation information are deeply fused, the powerful reasoning ability of the large language model is utilized, the complex and dynamic intentions of the disabled old people can be accurately recognized in a natural and low-cognitive-load mode, and the communication efficiency and the nursing quality are remarkably improved.